ANN ARBOR, Mich. – ENDRA Life Sciences Inc. (NASDAQ:), a developer of Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, has announced its return to compliance with Nasdaq’s minimum bid price requirement. The company received a notification from the Nasdaq Listing Qualifications Department on Thursday confirming that it now meets the continuous listing standards.
The Nasdaq compliance milestone follows the company’s strategic review shared during a conference call on August 22, 2024. “Now that we have regained compliance with Nasdaq’s listing requirements, we can focus all our efforts on making progress on our new transformational business strategies,” said Alex Tokman, acting Chief Executive Officer of ENDRA.
ENDRA Life Sciences is focused on the development of its TAEUS® technology, which is designed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures. The technology aims to…
